May 3 |
Keros Therapeutics files automatic mixed shelf
|
Apr 15 |
Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 37%?
|
Mar 14 |
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
|
Mar 5 |
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
|
Feb 28 |
Keros Therapeutics GAAP EPS of -$1.34 beats by $0.04, revenue of $0.14M
|
Feb 28 |
Keros Therapeutics Inc (KROS) Reports Increased R&D Spending and Net Loss in 2023
|
Feb 28 |
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
|
Feb 28 |
Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable
|
Feb 21 |
Does Keros Therapeutics, Inc. (KROS) Have the Potential to Rally 35.66% as Wall Street Analysts Expect?
|
Feb 12 |
Recent Price Trend in Keros Therapeutics, Inc. (KROS) is Your Friend, Here's Why
|